Xenobiotic-Metabolizing Enzymes Involved in Activation and Detoxification of Carcinogenic Polycyclic Aromatic Hydrocarbons

Conney, 1982, Induction of microsomal enzymes by foreign chemicals and carcinogenesis by polycyclic aromatic hydrocarbons: G. H. A. Clowes memorial lecture, Cancer Res., 42, 4875 Pelkonen, 1982, Metabolism of polycyclic aromatic hydrocarbons: etiologic role in carcinogenesis, Pharmacol. Rev., 34, 189 Hecht, 2002, Tobacco smoke carcinogens and breast cancer, Environm. Molec. Mutagen., 39, 119, 10.1002/em.10071 Levin, 1976, (±)-trans-7,8-dihydroxy-7,8-dihyd-robenzo[a]pyrene: a potent skin carcinogen when applied topically to mice, Proc. Natl., Acad. Sci. USA, 73, 3867, 10.1073/pnas.73.11.3867 Shimada, 2004, Metabolic activation of polycyclic aromatic hydrocarbons to carcinogens by cytochrome P450 1A1 and 1B1, Cancer Sci., 95, 1, 10.1111/j.1349-7006.2004.tb03162.x Cavalieri, 2005, Identification and quantification of the depurinating DNA adducts formed in mouse skin treated with dibenzo[a, l]pyrene (DB[a, l]P) or its metabolites and in rat mammary gland treated with DB[a, l]P, Chem. Res. Toxicol., 18, 976, 10.1021/tx049682k Melendez-Colon, 1999, Comparison of cytochrome P450- and peroxidase-dependent metabolic activation of the potent carcinogen dibenzo[a, l]pyrene in human cell lines: formation of stable DNA adducts and absence of a detectable increase in apurinic sites, Cancer Res., 59, 1412 Palackal, 2001, The ubiquitous aldehyde reductase (AKR1A1) oxidizes promimate carcinogen trans-dihydrodiols to o-quinones: potential role in polycyclic aromatic hydrocarbon activation, Chem. Res. Toxicol., 40, 10901 Jiang, 2005, Competing roles of cytochrome P450 1A1/1B1 and aldo-keto reductase 1A1 in the metabolic activation of (±)-7,8-dihydroxy 7,8-dihydro-benzo[a]pyrene in human bronchoalveolar cell extracts, Chem. Res. Toxicol., 18, 365, 10.1021/tx0497245 Joseph, 1994, NAD(P)H:quinone oxidoreductase1 (DT diaphorase) specifically prevents the formation of benzo[a]pyrene quinone-DNA adducts generated by cytochrome P450 1A1 and P450 reductase, Proc. Natl., Acad, Sci. USA, 91, 8413, 10.1073/pnas.91.18.8413 Long, 2000, NAD(P)H:quinone oxidoreductase 1 deficiency increases susceptibility to benzo[a]pyrene-induced mouse skin carcinogenesis, Cancer Res., 60, 5913 Kapitulnik, 1978, Tumorigenicity studies with diol-epoxides of benzo[a]pyrene which indicate that (±)-trans-7β,8α-dihydroxy-9α,10α-ep oxy-7,8,9,10-tetrahy drobenzo[a]pyrene is an ultimate carcinogen in newborn mice, Cancer Res., 38, 354 Xue, 2005, Metabolic activation of polycyclic and heterocyclic aromatic hydrocarbons and DNA damage: a review, Toxicol. Appl. Pharmacol., 206, 73, 10.1016/j.taap.2004.11.006 Ryan, 1990, Purification and characterization of hepatic microsomal cytochrome P-450, Pharmacol. Ther., 45, 153, 10.1016/0163-7258(90)90029-2 Pottenger, 1990, Characterization of a novel cytochrome P450 from the transformable cell line, C3H/10T1/2, Carcinogenesis, 11, 321, 10.1093/carcin/11.2.321 Otto, 1991, A novel adrenocorticotropin-inducible cytochrome P450 from rat adrenal microsomes catalyzes polycyclic aromatic hydrocarbon metabolism, Endocrinol., 129, 970, 10.1210/endo-129-2-970 Sutter, 1991, Targets for dioxin: genes for plasminogen activator inhibitor-2 and interleukin-1b, Science, 254, 415, 10.1126/science.1925598 Sutter, 1994, Complete cDNA sequence of a human dioxin-inducible mRNA identifies a new gene subfamily of cytochrome P450 that maps to chromosome 2, J. Biol. Chem., 269, 13092, 10.1016/S0021-9258(17)36803-5 Shimada, 1996, Activation of chemically diverse procarcinogens by human cytochrome P450 1B1, Cancer Res., 56, 2979 Shimada, 2001, Metabolic activation of polycyclic aromatic hydrocarbons and their dihydrodiol derivatives and other procarcinogens by cytochrome P450 1A1 and 1B1 allelic variants and other human cytochrome P450 enzymes in Salmonella typhimurium NM2009, Drug Metab. Disp., 29, 1176 LaVoie, 1982, Tumor initiating activity of dihydrodiols of benzo[b]fluoranthene, benzo[j]fluoranthene, and benzo[k]fluoranthene, Carcinogenesis, 3, 49, 10.1093/carcin/3.1.49 Amin, 1995, Tumorgenicity in nedwborn mice of fjord region and other sterically hindered diol epoxides of benzo[g]chrysene, dibenzo[a, l]pyrene (dibenzo[def, p]-chrysene). 4H-cyclopenta[def]chrysene and fluoranthene, Carcinogenesis, 16, 2813, 10.1093/carcin/16.11.2813 Wu, 2006, Recombinant enzymes overexpressed in bacteria show broad catalytic specificity of human cytochrome P450 2W1 and limited activity of human cytochrome P450 2S1, Mol. Pharmacol., 69, 2007, 10.1124/mol.106.023648 Buters, 1999, Cytochrome P450 CYP1B1 determines susceptibility to 7,12-dimethylbenz[a]anthracene-induced lymphomas, Proc. Nat. Acad. Sci. USA, 96, 1977, 10.1073/pnas.96.5.1977 Buters, 2002, Cytochrome P450 1B1 determines susceptibility to dibenzo[a, l]pyrene-induced tumor formation, Chem. Res. Toxicol., 15, 1127, 10.1021/tx020017q Luch, 1999, Metabolic activation of dibenzo[a]pyrene by human cytochrome P450 1A1 and P450 1B1 expressed in V79 Chinese hamster cells, Chem. Res. Toxicol., 12, 353, 10.1021/tx980240g Uno, 2004, Oral exposure to benzo[a]pyrene in the mouse: detoxication by inducible cytochrome P450 is more important than metabolic activation, Molec. Pharmacol., 65, 1225, 10.1124/mol.65.5.1225 Uno, 2006, Oral benzo [a] pyrene in Cyp1 knockout mice lines: CYP1A1 important in detoxication, CYP1B1 metabolism required for immune damage independent of total-body burden and clearance rate, Mol. Pharmacol., 69, 1103, 10.1124/mol.105.021501 Shimada, 1999, Metabolism of benzo[a]pyrene to trans-7,8-dihydroxy-7,8-dihydrobenzo[a]pyrene by recombinant human cytochrome P450 1B1 and purified liver epoxide hydrolase, Chem. Res. Toxicol., 12, 623, 10.1021/tx990028s Ding, 2003, Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts, Annu. Rev. Pharmacol. Toxicol., 43, 149, 10.1146/annurev.pharmtox.43.100901.140251 Murray, 2001, Regulation, function, and tissue-specific expression of cytochrome P450 CYP1B1, Annu. Rev. Pharmacol. Toxicol., 41, 297, 10.1146/annurev.pharmtox.41.1.297 Choudhary, 2005, Expression patterns of mouse and human CYP orthologs (families 1–4) during development and in different adult tissues, Arch. Biochem. Biophys., 436, 50, 10.1016/j.abb.2005.02.001 Hakkola, 1997, Expression of CYP1B1 in human adult and fetal tissues and differential inducibility of CYP1B1 and CYP1A1 by Ah receptor ligands in human placenta and cultured cells, Carcinogenesis, 18, 391, 10.1093/carcin/18.2.391 Murray, 1997, Tumor-specific expression of cytochrome P450 CYP1B1, Cancer Res., 57, 3026 Fujii-Kuriyama, 2005, Molecular mechanisms of AhR functions in the regulation of cytochrome P450 gene, Biochem. Biophys. Res. Commun., 338, 311, 10.1016/j.bbrc.2005.08.162 Nebert, 2004, Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer, J. Biol. Chem., 279, 23847, 10.1074/jbc.R400004200 Okey, 1994, The Ah receptor: mediator of the toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and related compounds, Toxicol. Lett., 70, 1, 10.1016/0378-4274(94)90139-2 Mimura, 1999, Identification of a novel mechanism of regulation of Ah (dioxin) receptor function, Genes Develop., 13, 20, 10.1101/gad.13.1.20 Mimura, 2003, Functional role of AhR in the expression of toxic effects by TCDD, Biochim. Biophys. Acta., 1619, 263, 10.1016/S0304-4165(02)00485-3 Zhang, 2003, Ah receptor regulation of mouse Cyp1B1 is additionally modulated by a second novel complex that forms at two AhR response elements, Toxicol. Appl. Pharmacol., 19, 174, 10.1016/S0041-008X(03)00276-X Fujii-Kuriyama, 1995, Polymorphic forms of the Ah receptor and induction of the CYP1A1 gene, Pharmacogenetics, 5, 149, 10.1097/00008571-199512001-00018 Poland, 1994, Analysis of the four alleles of the murine aryl hydrocarbon receptor, Mol. Pharmacol., 46, 915 Ema, 1994, Dioxin binding activities of polymorphic forms of mouse and human arylhydrocarbon receptors, J. Biol. Chem., 269, 27337, 10.1016/S0021-9258(18)46990-6 Harper, 2002, Polymorphisms in the human AH receptor, Chem-Biol. Interact., 141, 161, 10.1016/S0009-2797(02)00071-6 Dolwick, 1993, Cloning and expression of a human Ah receptor cDNA, Mol. Pharmacol., 44, 911 Moriguchi, 2003, Distinct response to dioxin in an arylhydrocarbon receptor (AHR)-humanized mouse, Proc. Natl. Acad. Sci. U S A., 100, 5652, 10.1073/pnas.1037886100 Shimada, 2002, Arylhydrocarbon receptor-dependent induction of liver and lung cytochromes P450 1A1, 1A2, and 1B1 by polycyclic aromatic hydrocarbons and polychlorinated biphenyls in genetically engineered C57BL/6J mice, Carcinogenesis, 23, 1199, 10.1093/carcin/23.7.1199 Shimada, 2003, Tissue-specific induction of cytochromes P450 1A1 and 1B1 by polycyclic aromatic hydrocarbons and polychlorinated biphenyls in engineered C57BL/6J mice of arylhydrocarbon receptor gene, Toxicol. Appl. Pharmacol., 187, 1, 10.1016/S0041-008X(02)00035-2 Shimada, 2003, Dose-response studies on the induction of liver cytochromes P4501A1 and 1B1 by polycyclic aromatic hydrocarbons in arylhydrocarbon-responsive C57BL/6J mice, Xenobiotica, 33, 957, 10.1080/0049825031000140896 Nebert, 1981, Genetic mechanisms controlling the induction of polysubstrate monooxygenase (P-450) activities, Annu. Rev. Pharmacol. Toxicol., 21, 431, 10.1146/annurev.pa.21.040181.002243 Poland, 1977, Chlorinated biphenyl induction of aryl hydrocarbon hydroxylase activity: a study of the structure-activity relationship, Mol. Pharmacol., 13, 924 Chun, 2003, Discovery of cytochrome P450 1B1 inhibitors as new promising anti-cancer agents, Med. Res. Rev., 23, 657, 10.1002/med.10050 Shimada, 1997, Inhibition of human cytochrome P450-catalyzed oxidations of xenobiotics and pro-carcino-gens by synthetic organoselenium compounds, Cancer Res., 57, 4757 Shimada, 1998, Selectivity of polycyclic inhibitors for human cytochromes P450 1A1, 1A2, and 1B1, Chem. Res. Toxicol., 11, 1048, 10.1021/tx980090+ Chun, 1999, Resveratrol is a selective human cytochrome P450 1A1 inhibitor, Biochem. Biophys. Res. Commun., 262, 20, 10.1006/bbrc.1999.1152 Chun, 2001, A new selective and potent inhibitor of human cytochrome P450 1B1 and its application to antimutagenesis, Cancer Res., 61, 8164 Gelboin, 1970, Dimethylbenzanthracene tumorigenesis and aryl hydrocarbon hydroxylase in mouse skin: inhibition by 7,8-benzoflavone, Science, 170, 169, 10.1126/science.170.3954.169 Kinoshita, 1972, Aryl hydrocarbon hydroxylase and polycyclic hydrocarbon tumorigenesis: effect of the enzyme inhibitor 7,8-benzoflavone on tumorigenesis and macromolecule binding, Proc. Nat. Acad. Sci. USA, 69, 824, 10.1073/pnas.69.4.824 Slaga, 1977, The effects of benzoflavones on polycyclic hydrocarbon metabolism and skin tumor initiation, Chem.-Biol. Int., 17, 297, 10.1016/0009-2797(77)90093-X El-Bayoumy, 1992, Inhibition of 7,12-dimethylbenz[a]anthracene-induced tumors and DNA adduct formation in the mammary glands of female Sprague-Dawley rats by the synthetic organoselenium compound, 1,4-phenylenebis (methy-lene) selenocyanate, Cancer Res., 52, 2402 Cai, 1997, Inhibitory effects of naturally occurring coumarins on the metabolic activation of benzo[a]pyrene and 7,12-dimethylbenz[a]anthracene in cultured mouse keratinocytes, Carcinogenesis, 18, 215, 10.1093/carcin/18.1.215 Jang, 1997, Cancer chemopreventive activity of resveratrol, a natural product derived from grapes, Science, 275, 218, 10.1126/science.275.5297.218 Kleiner, 2002, Role of cytochrome P450 1a1 and 1b1 in the metabolic activation of 7,12-dimethylbenz[a]anthracene and the effects of naturally ocurring furanocoumarins on skin tumor intitiation, Chem. Res. Toxicol., 15, 226, 10.1021/tx010151v Kleiner, 2003, Naturally occurring coumarins inhibit human cytochromes P450 and block benzo[a]pyrene and 7,12-dimethyl-benz[a]anthracene DNA adduct formation in MCF-7 cells, Chem. Res. Toxicol., 16, 415, 10.1021/tx025636d Ip, 1994, Comparative effect of inorganic and organic selenocyanate derivatives in mammary cancer chemoprevention, Carcinogenesis, 15, 187, 10.1093/carcin/15.2.187 Viaje, 1990, Inhibition of the binding of 7,12-dimethyl-benz[a]anthracene and benzo[a]pyrene to DNA in mouse skin epidermis by 1-ethynylpyrene, Carcinogenesis, 11, 1139, 10.1093/carcin/11.7.1139 Alworth, 1991, Potent inhibitory effects of suicide inhibitors of P450 isozymes on 7,12-dimethyl-benz[a]anthracene and benzo[a]pyrene initiated skin tumors, Carcinogenesis, 12, 1209, 10.1093/carcin/12.7.1209 Potter, 2002, The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1, British J. Cancer, 86, 774, 10.1038/sj.bjc.6600197 Shimada, 2006, Inhibition of human cytochrome P450 1A1-, 1A2-, and 1B1-mediated activation of procarcinogens to genotoxic metabolites by polycyclic aromatic hydrocarbons, Chem. Res. Toxicol., 19, 288, 10.1021/tx050291v Marston, 2001, Effect of a complex environmental mixture from coal tar containing polycyclic aromatic hydrocarbons (PAH) on the tumor initiation. PAH-DNA binding and metabolic activation of carcinogenic PAH in mouse epidermis, Carcinogenesis, 22, 1077, 10.1093/carcin/22.7.1077 Bartsch, 2000, Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers, Cancer Epidemiol. Biomarkers Prev., 9, 3 Williams, 2001, Single nucleotide polymorphisms, metabolic activation and environmental carcinogenesis: why molecular epidemiologists should think about enzyme expression, Carcinogenesis, 22, 209, 10.1093/carcin/22.2.209 Kiyohara, 2002, Genetic polymorphisms and lung cancer susceptibility: a review, Lung Cancer, 37, 241, 10.1016/S0169-5002(02)00107-1 Nagata, 2002, Genetic polymorphism of human cytochrome P450 involved in drug metabolism, Drug Metab. Pharmacokine., 17, 167, 10.2133/dmpk.17.167 Nebert, 1999, Genetic epidemiology of environmental toxicity and cancer susceptibility: human allelic polymorphisms in drug-metabolizing enzyme genes, their functional importance, and nomenclature issues, Drug Metab. Rev., 31, 467, 10.1081/DMR-100101931 Inoue, 2000, Ethnic-related differences in the frequency distribution of genetic polymorphisms in the CYP1A1 and CYP1B1 genes in Japanese and Caucasian populations, Xenobiotica, 30, 285, 10.1080/004982500237677 Kiyohara, 2002, Genetic polymorphism of enzymes involved in xenobiotic metabolism and the risk of lung cancer, Environm. Health Persp., 7, 47 Daly, 2003, Pharmacogenetics of the major polymorphic metabolizing enzymes, Fundam. Clin. Pharmacol., 17, 27, 10.1046/j.1472-8206.2003.00119.x Nebert, 1975, Genetic expression of aryl hydrocarbon hydroxylase activity in the mouse, J. Cell Physiol., 85, 393, 10.1002/jcp.1040850407 Shimada, 1992, Characterization of human lung microsomal cytochrome P-450 1A1 and its role in the oxidation of chemical carcinogens, Mol. Pharmacol., 41, 856 Jaiswal, 1985, Human P1–450 gene sequence and correlation of mRNA with genetic differences in benzo[a]pyrene metabolism, Nucleic Acids Res., 13, 4503, 10.1093/nar/13.12.4503 Shimada, 1997, Oxidation of xenobiotics by recombinant human cytochrome P450 1B1, Drug Metab. Disp., 25, 617 Spink, 1992, 17β-Estradiol hydroxylation catalyzed by human cytochrome P450 1a1: a comparison of the activities induced by 2,3,7,8-tetrachlorodibenzo-pdioxin in MCF-7 cells with those from heterologous expression of the cDNA, Arch. Biochem. Biophys, 293, 342, 10.1016/0003-9861(92)90404-K Rendic, 2002, Summary of information on human CYP enzymes: human P450 metabolism data, Drug Metab. Rev., 34, 83, 10.1081/DMR-120001392 Zhang, 1996, Characterization of purified recombinant human CYP 1A1-Ile462 and Val462: assessment of a role for the rare allele in carcinogenesis, Cancer Res., 56, 3926 Persson, 1997, In vitro kinetics of two human CYP1A1 variant enzymes suggested to be associated with interindividual differences in cancer susceptibility, Biochem. Biophys. Res. Commun., 231, 227, 10.1006/bbrc.1997.6051 Hayashi, 1991, Genetic linkage of lung cancer-associated Msp I polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P450IA1 gene, J. Biochem., 110, 407, 10.1093/oxfordjournals.jbchem.a123594 Kawajiri, 1991, P450 and human cancer, Jap. J. Cancer Res., 82, 1325, 10.1111/j.1349-7006.1991.tb01800.x Nakachi, 1993, Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population, Cancer Res., 53, 2994 Tefre, 1991, Human CYP1A1 (cytochrome P1 450) gene: lack of association between the Msp I restriction fragment length polymorphism and incidence of lung cancer in a Norwegian population, Pharmacogenetics, 1, 20, 10.1097/00008571-199110000-00004 Hirvonen, 1992, Point-mutational Msp1 and Ile-Val polymorphisms closely linked in the CYP1A1 gene: lack of association with susceptibility to lung cancer in a Finnish study population, Cancer Epidemiol. Biomarkers Prev., 1, 485 Masson, 2005, Cytochrome P-450 1A1 gene polymorphisms and risk of breast cancer: a HuGE review, Am. J. Epidemiol., 161, 901, 10.1093/aje/kwi121 London, 1995, Lung cancer risk in African-Americans in relation to a race-specific CYP1A1 polymorphism, Cancer Res., 55, 6035 Taioli, 1995, A specific African-American CYP1A1 polymorphism is associated with adenocarcinoma of the lung, Cancer Res., 55, 472 London, 2000, CYP1A1 I462V genetic polymorphism and lung cancer risk in a cohort of men in Shanghai, China. Cancer Epidemiol. Biomarkers Prev., 9, 987 Cascorbi, 1996, A C4887A polymorphism in exon 7 of human CYP1A1: populaiton frequency, mutation linkages, and impact on lung cancer susceptibility, Cancer Res., 56, 4965 Crofts, 1993, A novel CYP1A1 gene polymorphism in African-Americans, Carcinogenesis, 14, 1729, 10.1093/carcin/14.9.1729 Aynacioglu, 1998, High frequency of CYP1A1 mutations in a Turkish population, Arch. Toxicol., 72, 215, 10.1007/s002040050491 Shimada, 1994, Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens, and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians, J. Pharmacol. Exp. Ther., 270, 414 Distlerath, 1985, Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxy-lation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism, J. Biol. Chem., 260, 9057, 10.1016/S0021-9258(17)39456-5 Jaiswal, 1987, Human P3–450: cDNA and complete protein sequence, repetitive Alu sequences in the 3′ nontranslated region, and localization of gene to chromosome 15, J. Exp. Path., 3, 1 Guengerich, 1991, Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes, Chem. Res. Toxicol., 4, 391, 10.1021/tx00022a001 Shimada, 1988, Metabolic activation of environmental carcinogens and mutagens by human liver microsomes: role of cytochrome P-450 homologous to 3-methylcholanthrene-inducible isozyme in rat liver, Biochem. Pharmacol., 37, 459, 10.1016/0006-2952(88)90215-8 Shimada, 1989, Human liver microsomal cytochrome P-450 enzymes involved in the bioactivation of procarcinogens detected by umu gene response in Salmonella typhimurium TA1535/pSK1002, Cancer Res., 49, 3218 Shimada, 1989, Roles of individual human cytochrome P-450 enzymes in the bioactivation of benzo[a]pyrene, 7,8-dihydroxy-7,8-dihydroben-zo[a]pyrene, and other dihydrodiol derivatives of polycyclic aromatic hydrocarbons, Cancer Res., 49, 6304 Allorge, 2003, Identification of a novel splice-site mutation in the CYP1A2 gene, Br. J. Clin. Pharmacol., 56, 341, 10.1046/j.1365-2125.2003.01858.x Nakajima, 1999, Genetic polymorphism in the 5′-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans, J. Biochem. (Tokyo), 125, 803, 10.1093/oxfordjournals.jbchem.a022352 Aklillu, 2003, Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1, Molec. Pharmacol., 64, 659, 10.1124/mol.64.3.659 Chida, 1999, Detection of three genetic polymorphisms in the 5′-flanking region and intron 1 of human CYP1A2 in the Japanese population, Jpn. J. Cancer Res., 90, 899, 10.1111/j.1349-7006.1999.tb00832.x Murayama, 2004, Six novel nonsynonymous CYP1A2 gene polymorphisms: catalytic activities of the naturally occurring variant enzymes, J. Pharmacol. Exp. Ther., 308, 300, 10.1124/jpet.103.055798 Tang, 1996, Isolation and characterization of the human cytochrome P450 CYP1B1 gene, J. Biol. Chem., 271, 28324, 10.1074/jbc.271.45.28324 Walker, 1995, Rat CYP1B1: an adrenal cytochrome P450 that exhibits sex-dependent expression in livers and kidneys of TCDD-treated animals, Carcinogenesis, 16, 1319, 10.1093/carcin/16.6.1319 Spink, 1998, Differential expression of CYP1A1 and CYP1B1 in human breast epithelial cells and breast tumor cells, Carcinogenesis, 19, 291, 10.1093/carcin/19.2.291 Baron, 1998, Cytochrome P450 1B1: a major P450 isoenzyme in human blood monocytes and macrophage subsets, Biochem. Pharmacol., 56, 1105, 10.1016/S0006-2952(98)00105-1 Spencer, 1999, Quantitative analysis of consitiutive and 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced cytochrome P450 1B1 expression in human lymphocytes, Cancer Epidemiol. Biomarkers Prev., 8, 139 Huang, 1996, Expression of cytochromes P450 in human breast tissue and tumors, Drug Metab. Disp., 24, 899 Liehr, 1995, 4-Hydroxylation of estradiol by human uterine myometrium and myoma microsomes: implications for the mechanism of uterine tumorigenesis, Proc. Nat. Aca. Sci. USA, 92, 9220, 10.1073/pnas.92.20.9220 Shimada, 1999, Human cytochrome P450 1B1 and chemical carcinogenesis, Rev. Toxicol., 3, 139 Stoilov, 1998, Sequence analysis and homology modeling suggest that primary congenital glaucoma on 2p21 results from mutations disrupting either the hinge region or the conserved core structures of cytochrome P4501B1, Am. J. Hum. Genet., 62, 573, 10.1086/301764 Stoilov, 1997, Identification of three different truncating mutations in cytochrome P4501B1 (CYP1B1) as the principal cause of primary congenital glaucoma (Buphthalmos) in families linked to the GLC3A locus on chromosome 2p21, Hum. Mol. Genet., 6, 641, 10.1093/hmg/6.4.641 Bailey, 1998, Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer, Cancer Res., 58, 5038 Fritsche, 1999, Detection of cytochrome P450 1B1 Bfr I polymorphism: genotype distribution in healthy German individuals and in patients with colorectal carcinoma, Pharmacogenetics, 9, 405, 10.1097/00008571-199906000-00018 Shimada, 2001, Specificity of 17β-oestradiol and benzo[a]pyrene oxidation by polymorphic human cytochrome P450 1B1 variants substituted at residues 48, 119, and 432, Xenobiotica, 31, 163, 10.1080/00498250110043490 Watanabe, 2000, Association of CYP1B1 genetic polymorphism with incidence to breast and lung cancer, Pharmacogenetics, 10, 25, 10.1097/00008571-200002000-00004 Zheng, 2000, Genetic polymorphism of cytochrome P450 1B1 and risk of breast cancer, Cancer Epidem. Biomarker Prev., 9, 147 Rylander-Rudqvist, 2003, Cytochrome P450 1B1 gene polymorphisms and postmenopausal breast cancer risk, Carcinogenesis, 24, 1533, 10.1093/carcin/bgg114 Sorensen, 2005, Genetic polymorphisms in CYP1B1, GSTA1, NQO1, and NAT2 and the risk of lung cancer, Cancer Lett., 221, 185, 10.1016/j.canlet.2004.11.012 Yamazaki, 1998, Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidations of warfarin, flurbiprofen, and diclofenac by human liver microsomes, Biochem. Pharmacol., 56, 243, 10.1016/S0006-2952(98)00133-6 Yun, 1992, Roles of human liver cytochrome P-4502C and 3A enzymes in the 3-hydroxylation of benzo[a]pyrene, Cancer Res., 52, 1868 Rettie, 1994, Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9, Pharmacogenetics, 4, 39, 10.1097/00008571-199402000-00005 Sullivan-Klose, 1996, The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism, Pharmacogenetics, 6, 341, 10.1097/00008571-199608000-00007 Haining, 1996, Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms, Arch. Biochem. Biophys., 333, 447, 10.1006/abbi.1996.0414 Takahashi, 2003, Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients, Clin. Pharmacol. Ther., 73, 253, 10.1067/mcp.2003.26a Dickmann, 2001, Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans, Mol. Pharmacol., 60, 382, 10.1124/mol.60.2.382 Garcia-Martin, 2002, Influence of cytochrome P450 CYP2C9 genotypes in lung cancer risk, Cancer Lett., 180, 41, 10.1016/S0304-3835(02)00015-0 Wrighton, 2000, The human CYP3A subfamily: practical considerations, Drug Metab. Rev., 32, 339, 10.1081/DMR-100102338 Dai, 2001, Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos, J. Pharmacol. Exp. Ther, 299, 825 Morisseau, 2005, Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles, Annu. Rev. Pharmacol. Toxicol., 45, 311, 10.1146/annurev.pharmtox.45.120403.095920 Miyata, 1999, Targeted disruption of the microsomal epoxide hydrolase gene. Microsomal epoxide hydrolase is required for the carcinogenic activity of 7,12-dimethylbenz[a]anthracene, J. Biol. Chem., 274, 23963, 10.1074/jbc.274.34.23963 Lee, 2002, Microsomal epoxide hydrolase polymorphisms and lung cancer risk: a quantitative review, Biomarkers, 7, 230, 10.1080/13547500210121882 Hosagrahara, 2004, Functional analysis of human microsomal epoxide hydrolase genetic variants, Chem.-Biol. Interact., 150, 149, 10.1016/j.cbi.2004.07.004 Park, 2005, Genetic analysis of microsomal epoxide hydrolase gene and its association with lung cancer risk, Eur. J. Cancer Prev., 14, 223, 10.1097/00008469-200506000-00005 Gsur, 2003, Association of microsomal epoxide hydrolase polymorphisms and lung cancer risk, Br. J. Cancer, 89, 702, 10.1038/sj.bjc.6601142 de Assis, 2002, Microsomal epoxide hydrolase variants are not associated with risk of breast cancer, Cancer Epidemiol. Biomarkers Prev., 11, 1697 Huang, 2005, Microsomal epoxide hydrolase polymorphisms and risk for advanced colorectal adenoma, Cancer Epidemiol. Biomarkers Prev., 14, 152, 10.1158/1055-9965.152.14.1 Strange, 2001, Glutathione-S-transferase family of enzymes, Mutat. Res., 482, 21, 10.1016/S0027-5107(01)00206-8 Hayes, 2005, Glutathione transferases, Ann. Rev. Pharmacol. Toxicol., 45, 51, 10.1146/annurev.pharmtox.45.120403.095857 Bartsch, 1999, Genetic cancer susceptibility and DNA adducts: studies in smokers, tobacco chewers, and coke oven workers, Cancer Detect. Prev., 23, 445, 10.1046/j.1525-1500.1999.99055.x Wang, 2003, GST genetic polymorphisms and lung adenocarcinoma susceptibility in a Chinese population, Cancer Lett., 201, 185, 10.1016/S0304-3835(03)00480-4 Vogl, 2004, Glutathione S-transferases M1, T1, and P1 and breast cancer: a pooled analysis, Cancer Epidemiol. Biomarkers Prev., 13, 1473, 10.1158/1055-9965.1473.13.9 Ntais, 2005, Association of GSTM1, GSTT1, and GSTP1 gene polymorphisms with the risk of prostate cancer: a meta-analysis, Cancer Epidemiol. Biomarkers Prev., 14, 176, 10.1158/1055-9965.176.14.1 Spurdle, 2001, Polymorphisms at the glutathione S-transferase GSTM1, GSTT1 and GSTP1 loci: risk of ovarian cancer by histological subtype, Carcinogenesis, 22, 67, 10.1093/carcin/22.1.67 Kidd, 2003, Polymorphisms in glutathione-S-transferase genes (GST-M1, GST-T1 and GST-P1) and susceptibility to prostate cancer among male smokers of the ATBC cancer prevention study, Eur. J. Cancer Prev., 12, 317, 10.1097/00008469-200308000-00012 Mckenzie, 2005, Nomenclature update for the mammarian UDP glucuronyltransferase (UGT) gene, Pharmacogenet. Genomics, 15, 677, 10.1097/01.fpc.0000173483.13689.56 Guillemette, 2000, Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and association with breast cancer among African Americans, Cancer Res., 60, 950 Jinno, 2003, Functional characterization of human UDP-glucuronosyltransferase 1A9 variant, D256N, found in Japanese cancer patients, J. Pharmacol. Exp. Ther., 306, 688, 10.1124/jpet.103.051250 Vogel, 2002, Polymorphisms of the carcinogen detoxifying UDP-glucuronosyltransferase UGT1A7 in proximal digestive tract cancer, Z. Gastroenterol., 40, 497, 10.1055/s-2002-32805 Gamage, 2006, Human sulfotransferases and their roles in chemical metabolism, Toxicol. Sci., 90, 5, 10.1093/toxsci/kfj061 Watabe, 1982, A 7-hydroxymethyl sulfate ester as an active metabolite of 7,12-dimethylbenz[a]anthracene, Science, 215, 403, 10.1126/science.6800033 Surh, 1995, Sulfotransferase-mediated activation of 7,8,9,10-tetrahydro-7-ol, 7,8-dihydrodiol, and 7,8,9,10-tetraol derivatives of benzo[a]pyrene, Chem. Res. Toxicol., 8, 693, 10.1021/tx00047a008 Raftogianis, 1997, Phenol sulfotransferase pharmacogenetics in humans: association of common SULT1A1 alleles with TS PST phenotype, Biochem. Biophys. Res. Commun., 239, 298, 10.1006/bbrc.1997.7466 Raftogianis, 1999, Human phenol sulfotransferases SULT1A2 and SULT1A1: genetic polymorphisms, allozyme properties, and human liver genotype-phenotype correlations, Biochem. Pharmacol., 58, 605, 10.1016/S0006-2952(99)00145-8 Wang, 2002, Sulfotransferase (SULT) 1A1 polymorphism as a predisposition factor for lung cancer: a case-control analysis, Lung Cancer, 35, 137, 10.1016/S0169-5002(01)00406-8 Zheng, 2003, Sulfotransferase 1A1 (SULT1A1) polymorphism and bladder cancer risk: a case-control study, Cancer Lett., 202, 61, 10.1016/j.canlet.2003.08.007 Lilla, 2005, SULT1A1 genotype, active and passive smoking, and breast cancer risk by age 50 years in a German case-control study, Breast Cancer Res., 7, R229, 10.1186/bcr976 Ross, 2004, NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase), functions and pharmacogenetics, Methods Enzymol., 382, 115, 10.1016/S0076-6879(04)82008-1 Long, 2001, NAD(P)H:quinone oxidoreductase 1 deficiency and increased susceptibility to 7,12-dimethylbenz[a]-anthracene-induced carcinogenesis in mouse skin, J. Natl. Cancer Inst., 93, 1166, 10.1093/jnci/93.15.1166 Sharp, 2000, Establishment of an isogenic human colon tumor model for NQO1 gene expression: application to investigate the role of DT-diaphorase in bioreductive drug activation in vitro and in vivo, Mol. Pharmacol., 58, 1146, 10.1124/mol.58.5.1146 Saldivar, 2005, An association between a NQO1 genetic polymorphism and risk of lung cancer, Mutat. Res., 582, 71, 10.1016/j.mrgentox.2004.12.010 Lewis, 2001, Polymorphisms in the NAD(P)H: quinone oxidoreductase gene and small cell lung cancer risk in a UK population, Lung Cancer, 34, 177, 10.1016/S0169-5002(01)00243-4 Sunaga, 2002, Contribution of the NQO1 and GSTT1 polymorphisms to lung adenocarcinoma susceptibility, Cancer Epidemiol. Biomarkers Prev., 11, 730 Chen, 1999, Association of the NAD(P)H:qui-none oxidoreductase 609C→T Polymorphism with a decreased lung cancer risk, Cancer Res., 59, 3045 Niwa, 2005, Association of the NAD(P)H: quinone oxidoreductase C609T polymorphism and the risk of cervical cancer in Japanese subjects, Gynecol. Oncol., 96, 423, 10.1016/j.ygyno.2004.10.015 Penning, 2004, Aldo-keto reductases and formation of polycyclic aromatic hydrocarbon o-quinones, Methods Enzymol., 378, 31, 10.1016/S0076-6879(04)78003-9 Hyndman, 2003, The aldo-keto reductase superfamily homepage, Chem. Biol. Interact., 143–144, 621, 10.1016/S0009-2797(02)00193-X